Friday's Health Winners & Losers
Shares of drug developer Genta (GNTA) sank 24.5% to 52 cents Friday after the company announced that regulators have deemed its proposed blood cancer treatment Genasense not approvable. The drug was intended to treat chronic lymphocytic leukemia, in combination with chemotherapy.
Shares of drug developer Biopure (BPUR) plummeted 27% to 43 cents after a Food and Drug Administration panel recommended against a clinical trial as currently designed. The agency's blood products advisory committee voted 11 to 8, with one abstention, against an 1,100-patient trial in favor of a smaller safety and efficacy trial.
Meanwhile, Critical Therapeutics' (CRTX) shares gained 25.2% to $1.90 after the company announced that a study of its lung disease drug Zyflo will be funded by the National Institutes of Health. The trial is designed to evaluate whether the drug can help shorten hospital stays of patients admitted with acute exacerbations of chronic obstructive pulmonary disease. The trial is expected to begin in the first quarter of 2007.
Genzyme's (GENZ) shares rose 3.3% to $63.07 Friday after the company said its arthritis treatment Synvisc will maintain its own reimbursement code and rate in 2007. The Centers for Medicare and Medicaid Services previously said all treatments like Synvisc would use the same billing code, a move that was expected to lower reimbursement for the knee injection.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV